Literature DB >> 1759827

Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

F Vallée1, M LeBel.   

Abstract

Single 2-g intravenous doses of ceftizoxime (CZX) and cefotaxime (CTX) were given over 30 min to 10 adult volunteers in a crossover manner on two separate occasions. Concentrations of CZX, CTX, and the primary metabolite of CTX, desacetylcefotaxime (dCTX), in serum, suction-induced-blister fluid, and urine were determined by high-pressure liquid chromatography. Pharmacokinetic parameters were estimated by using an extended least-squares modeling program (MKMODEL). CZX exhibited a half-life in serum (2.05 h) longer than that of CTX (1.43 h) but comparable to that of dCTX (2.02 h). The percentage of penetration in blister fluid, estimated by area under the curve ratios, was significantly higher for CZX (164.4%) than for CTX (60.8%). Serum bactericidal activity, determined for volunteer samples at 1, 6, 8, and 12 h after patients were dosed, against clinical isolates of the Bacteroides fragilis group, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and Morganella morganii were significantly higher for CZX than those for CTX against members of the family Enterobacteriaceae at all times. Serum bactericidal titers against B. fragilis were also higher for CZX than for CTX at 1 h postinfusion. Neither CZX nor CTX exhibited any bactericidal activity at any other time against the B. fragilis group. In conclusion, the serum bactericidal activity of CZX was greater and more-prolonged than that of CTX against tested strains in spite of the in vitro synergistic contribution of dCTX to CTX, equal serum elimination half-lives of dCTX and CZX, and similar antibacterial activity and similar instability under microbiological testing for CZX and CTX.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759827      PMCID: PMC245326          DOI: 10.1128/AAC.35.10.2057

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.

Authors:  B L Wasilauskas
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

2.  Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.

Authors:  H N Canawati
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

3.  Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.

Authors:  S G Jenkins
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

4.  Additive and synergistic bactericidal activity contributed by desacetylcefotaxime during cefotaxime therapy.

Authors:  E S Moore; M Jimenez; S L Barriere; M L Cimino; F R Fekety
Journal:  Clin Pharm       Date:  1988-12

5.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

6.  Impaired clearance of ceftizoxime and cefotaxime after orthotopic liver transplantation.

Authors:  G J Burckart; R J Ptachcinski; D H Jones; D L Howrie; R Venkataramanan; T E Starzl
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

Authors:  K Oizumi; I Hayashi; S Aonuma; K Konno
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.

Authors:  K E Aldridge; L S Weeks; C W Stratton; C V Sanders
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Mar-Apr       Impact factor: 2.803

10.  Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.

Authors:  S L Barriere; D C Ozasa; J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  11 in total

1.  Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.

Authors:  A R H van Zanten; M Oudijk; M K E Nohlmans-Paulssen; Y G van der Meer; A R J Girbes; K H Polderman
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

2.  Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants.

Authors:  Xing-Kai Chen; Hai-Yan Shi; Stephanie Leroux; Hai-Yan Xu; Yue Zhou; Yi Zheng; Xin Huang; Yan Li; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Authors:  D E Nix; J H Wilton; J Hyatt; J Thomas; L C Strenkoski-Nix; A Forrest; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Validation and Application of an LC-MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine.

Authors:  Lu Wang; Xin Zheng; Wen Zhong; Jia Chen; Ji Jiang; Pei Hu
Journal:  J Chromatogr Sci       Date:  2016-02-18       Impact factor: 1.618

5.  Comparative serum bactericidal activities of ceftizoxime and cefotaxime against intermediately penicillin-resistant Streptococcus pneumoniae.

Authors:  K B Patel; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 6.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

8.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients.

Authors:  B Facca; B Frame; S Triesenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

10.  Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.

Authors:  Chen Huang; Beiwen Zheng; Wei Yu; Tianshui Niu; Tingting Xiao; Jing Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-01-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.